BioSpace News Archive

ZyVersa Therapeutics, Inc. announces that Dr. Richard J. Glassock has joined ZyVersa’s Renal Scientific Advisory Board.

Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration Implant, announced it has entered into a distribution agreement with Veteran’s Health Medical Supply.

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of the third cohort of eight healthy participants in its Phase 1 clinical trial of its lead product candidate

Economic activity in the hospital subsector grew in February for the 33rd consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.

X-Bolt has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Pro-X1 will be X-Bolt’s flagship launch in the United States.

INITIO Medical Group is the first private nuclear medicine facility in Canada to be awarded a therapeutic license to administer Lutetium-177-PSMA (prostate specific membrane antigen) for the treatment of advanced prostate cancer, specifically “metastatic castration resistant prostate cancer” also known as “mCRPC”.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2022.

BioMarin Pharmaceutical Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for injection to expand treatment in the United States to include children with achondroplasia under the age of 5.

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2022, and provided an update on business progress.